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The native cottontail rabbit papillomavirus (CRPV) L1 capsid protein gene was expressed transgenically via
Agrobacterium tumefaciens transformation and transiently via a tobacco mosaic virus (TMV) vector in Nicotiana
spp. L1 protein was detected in concentrated plant extracts at concentrations up to 1.0 mg/kg in transgenic
plants and up to 0.4 mg/kg in TMV-infected plants. The protein did not detectably assemble into viruslike
particles; however, immunoelectron microscopy showed presumptive pentamer aggregates, and extracted
protein reacted with conformation-specific and neutralizing monoclonal antibodies. Rabbits were injected with
concentrated protein extract with Freund’s incomplete adjuvant. All sera reacted with baculovirus-produced
CRPV L1; however, they did not detectably neutralize infectivity in an in vitro assay. Vaccinated rabbits were,
however, protected against wart development on subsequent challenge with live virus. This is the first evidence
that a plant-derived papillomavirus vaccine is protective in an animal model and is a proof of concept for
human papillomavirus vaccines produced in plants.
Papillomaviruses (PVs) are small double-stranded DNA vi-
ruses (family Papillomaviridae) that infect many different ver-
tebrate species (12). Human papillomaviruses (HPV) are
known to cause warts and have also been associated with cer-
tain cancers in humans (46). Specific high-risk types of HPV
are causally associated with cervical cancer (43); this is the
second most prevalent cancer in women worldwide and the
most common cancer in South African women (30). Vaccina-
tion against papillomaviral disease should result in reduced
disease burden, which has resulted in a worldwide effort to
develop prophylactic vaccines against HPV.
The efforts to develop candidate HPV vaccines have been
made more difficult by the fact that the protective efficacy of
vaccines cannot be evaluated in animals. In contrast, however,
development of animal PV vaccines allows evaluation by im-
munization of the respective hosts, followed by an experimen-
tal challenge with live virus. Cottontail rabbit papillomavirus
(CRPV) in rabbits provides a robust model to study viral in-
teraction with the host and progression to cancer and for viral
vaccine studies. Naive domestic rabbits can be protected from
experimental challenge with live CRPV after vaccination with
a nondenatured L1 and/or whole L2 protein or peptides de-
rived from the L2 protein (2, 5, 8, 9, 24, 27, 28).
The most successful HPV prophylactic vaccine candidates to
date are based on L1 viruslike particles (VLPs) produced by
recombinant baculovirus and yeast: these VLPs are almost
indistinguishable from native virions in morphology and induce
effectively identical immune responses (for a review see refer-
ence 30). In animal and human studies, VLP vaccines have
been well tolerated and have induced high titers of neutralizing
antibodies as well as protecting against papillomaviral infec-
tion and especially disease (3, 22). However, these vaccines will
be expensive and not affordable in developing countries where
they are needed most (37, 39).
Plants have been investigated extensively recently as alter-
native and cheaper production vehicles for vaccines and other
high-value pharmaceuticals: proteins can be expressed in
plants which have been stably transformed or transiently trans-
formed by use of plant viral vectors or by infiltration with
Agrobacterium tumefaciens (15, 16). In particular, it is thought
that gene expression can be significantly increased over the
transgenic case by utilizing recombinant tobacco mosaic virus
(TMV) vectors (20). We and others have previously reported
the transgenic expression of HPV-16 L1 in tobacco and pota-
toes (1, 29, 40, 44), and we have recently reported the use of a
TMV-based plant virus vector to express HPV-16 L1 tran-
siently in Nicotiana benthamiana (41). However, in all cases
except for a human codon usage-optimized HPV-16 L1 gene in
tobacco (1), expression levels were very low and the immuno-
genicity of the products, whether administered orally or by
injection, was uniformly low. Moreover, it has not yet been
shown in these five published reports of plant expression of
HPV L1 proteins that these proteins elicit either neutralizing
antibodies or protection from disease.
Here we focus on the evaluation of a plant-produced CRPV
vaccine, which was produced in plants by expressing the native
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L1 gene either transiently using a TMV-based vector or in
Agrobacterium tumefaciens-transformed transgenic plants. We
investigated whether a plant-derived PV vaccine was indeed
capable of eliciting an immune response similar or identical to
that achieved by vaccination of animals with recombinant-
baculovirus-produced VLPs. We further investigated whether
protective immunity was established after vaccination of New
Zealand White rabbits with plant-derived CRPV VLPs in vivo
by challenging animals with live virus.
MATERIALS AND METHODS
Cloning of the CRPV L1 gene. The CRPV L1 full-length gene was amplified
by PCR using the following primer pair: Forward, 5-TTAATTAAATGGCAG
TGTGGCTGTCTACG-3 (PacI site is underlined; start codon is in boldface);
Reverse, 5-CTCGAGTTAAGTTCTCTTGCGTTTAGATGATTTC-3 (XhoI
site is underlined; stop codon is in boldface) from a full-length CRPV virus clone
(N. D. Christensen). The PCR product was cloned into the pGEM-T Easy vector
(Promega), and the sequence was verified.
The CRPV L1 gene was directionally subcloned using PacI and XhoI into the
Geneware vector pBSG1057 (Large Scale Biology Corporation, Vacaville,
Calif.), thereby replacing the 30B-GFPC3 gene. It was also cloned into the
Agrobacterium vector pART7 using EcoRI. The cassette containing the CRPV
L1 gene, the CaMV35S promoter, and the octopine synthase gene terminator
(ocs 3) was excised by NotI digestion and subcloned into the binary vector
pART27 (19).
Transformation of Nicotiana tabacum cv. Xanthi. N. tabacum leaf disks were
transformed with A. tumefaciens carrying the pART27 CRPV L1 binary vector,
and transgenic plants were regenerated according to a standard protocol (23).
Flowering regenerated plants (R0 generation) were self-pollinated and the seeds
collected. Dry seeds were screened on plant tissue culture media containing
kanamycin (250 g/ml), and putative transgenic seedlings were transferred to
soil, once the fourth leaves had grown to maturity.
Screening of transformed N. tabacum plants for the CRPV L1 gene. Plant
genomic DNA was extracted in extraction buffer (100 mM Tris, 50 mM EDTA,
500 mM NaCl, pH 8.0) from putative transgenic and wild-type N. tabacum leaves
using the Dellaporta method (11). DNA from transformed N. tabacum plants
was screened by PCR for the CRPV L1 gene using the same primer pair and
conditions as those used for the initial amplification of the gene.
Inoculation of Nicotiana benthamiana plants with CRPV RNA. Transcripts
were synthesized in vitro using the T7 RNA polymerase (RiboMAX large-scale
RNA production system T7; Promega) and capped by addition of the RNA cap
structure analogue m7G(5)ppp(5)G (New England Biolabs).
Inoculation of 3-week-old N. benthamiana plants and subsequent monitoring
of infection were done as described previously (41).
Analysis of total plant RNA extracts. Total RNA was extracted from fresh leaf
material from transgenic plants and from individual leaves from TMV-infected
plants at 14 days postinoculation using the TRIzol reagent (Life Technologies).
Total RNA samples were predigested with RNase-free DNase (Promega) at
37°C for 30 min. DNase stop solution was added to the samples, and the DNase
was heat inactivated at 65°C for 10 min. CRPV L1 RNA was amplified by reverse
transcription-PCR (RT-PCR) using the Access RT-PCR system (Promega). For
CRPV, forward primer 5-AAAGCATGGCGTTCGACC-3 and reverse primer
5-GCACACAGATGCAGGGAGAG-3 were used to amplify an internal, 421-
base-pair fragment situated between nucleotides 433 and 854. TMV coat protein
mRNA was amplified from TMV-infected plants using forward primer 5-CA
TTAGCGCTGCGGCCGCCCTTATACAATCAACTCTCCG-3 and reverse
primer 5-ATAAGAATGCGGCGGCTCGCGAAGTAGCCGGAGTTGTTGT
C-3, which gives a 474-bp product.
Processing and concentration of plant material. Leaf material was harvested
and homogenized in 1:2 (wt/vol) cold high-salt phosphate-buffered saline (PBS;
1.47 mM KH2PO4, 10 mM Na2HPO4, 2.7 mM KCl, 500 mM NaCl, pH 7.4).
Homogenate was filtered through cheesecloth and centrifuged at 6,000 g for 10
min to remove plant debris. To precipitate TMV particles in the TMV-infected
plants, 4% polyethylene glycol (PEG; molecular weight, 8,000) was added to the
supernatant and it was centrifuged at 6,000  g for 20 min. Six percent PEG was
added to the subsequent supernatant. Transgenic plant material was treated
directly with 10% PEG and centrifuged at 6,000  g for 20 min. The resulting
pellet was resuspended in 1/10 starting volume of PBS, the suspension was
centrifuged for 20 min at 6,000  g, and the supernatant was then centrifuged at
100,000  g for 2 h to pellet high-molecular-weight aggregates. Pellets were
resuspended in 1/10 starting volume and further analyzed by enzyme-linked
immunosorbent assay (ELISA) and electron microscopy.
Monoclonal antibody characterization of plant-derived protein. CRPV L1
protein-containing extracts derived from N. tabacum and N. benthamiana to-
gether with nontransgenic plant protein extracts were characterized by direct
ELISA using two monoclonal antibodies (MAbs) against CRPV. Monoclonal
antibody CRPV:5A is a conformation-specific neutralizing antibody, and CRPV:
10B recognizes a linear surface epitope (7). ELISA plates were coated with
protein extracts for 1 h and then blocked in 2% nonfat milk in PBS (1.47 mM
KH2PO4, 10 mM Na2HPO4, 2.7 mM KCl, 137 mM NaCl, pH 7.4) for 1 h. MAbs
diluted at 1:1,000 were incubated with the plant-derived antigen for 1 h. Anti-
mouse immunoglobulin G-alkaline phosphatase-conjugated secondary antibody
(diluted 1:5,000; Sigma) was allowed to bind the primary antibody for 1 h at 37°C.
The secondary antibody was detected using p-nitrophenylphosphate (Sigma),
and the absorbance was measured using a Titrex ELISA plate reader at 405 nm.
All samples were analyzed in triplicate to determine the mean absorbance and
calculate the respective standard deviation.
Expression of the CRPV L1 gene in Sf21 cells via recombinant baculovirus.
The CRPV L1 gene was directionally cloned into the pFastBac1 vector (Invitro-
gen) using the EcoRI restriction enzyme sites. This DNA was used for the
transfection of maximum-efficiency DH10Bac-competent Escherichia coli cells
for the preparation of bacmid clones. Recombinant bacmid DNA was isolated
and used for transfection of Spodoptera frugiperda (Sf21) cells (Invitrogen) in the
presence of Cellfectin (Invitrogen) according to the manufacturer’s Bac-to-Bac
protocol.
To purify CRPV L1 VLPs, Sf21 cells were pelleted, resuspended in PBS
containing 0.4 g/ml CsCl and complete protease inhibitor (Roche), and soni-
cated. The sonicated suspension was centrifuged at 100,000  g at 10°C for 24 h.
Two distinct bands were observed on the CsCl gradient: the top band was
extracted by puncturing the tubes and dialyzed against PBS (1.47 mM KH2PO4,
10 mM Na2HPO4, 2.7 mM KCl, 500 mM NaCl, pH 7.4) for 48 h. Dialyzed protein
was divided into 100-l aliquots and frozen at 70°C for further use.
Electron microscopy of plant-derived CRPV L1 protein. Protein extracts from
transgenic and infected plants and insect cell-derived CRPV L1 VLPs were
viewed under the electron microscope after absorption of the respective prepa-
rations onto carbon-coated copper grids for direct viewing or L1 protein detec-
tion by immunogold labeling.
Basic procedures were done as described previously (40). Protein samples
were directly adsorbed onto copper grids for 30 min and then stained in 2%
uranyl acetate for 2 min. Immunotrapping of plant- and insect cell-derived L1
protein was done with rabbit anti-CRPV L1 antiserum raised against insect
cell-derived CRPV L1 VLPs diluted 1:50 in PBS. Grids were incubated with
plant protein extract for 30 min, washed, and stained in 2% uranyl acetate for
2 min.
For immunogold labeling, immunotrapping of transgenic, transiently express-
ing, and nontransgenic plant protein extracts was done as described above. Grids
were then washed and probed with CRPV L1 MAbs CRPV:5A and CRPV:10B
(diluted 1:1,000 in 1% bovine serum albumin-PBS) for 60 min at room temper-
ature. Another 2-min washing step preceded the 60-min incubation of grids in
the gold-labeled anti-mouse immunoglobulin G-conjugated secondary antibody
(30-nm gold particles) diluted 1:100 in PBS. Grids were washed one final time in
sterile distilled water (twice for 2 min each) before being stained with 2% uranyl
acetate for 2 min.
Immunization of rabbits and evaluation of sera. Two groups of three New
Zealand White rabbits each were inoculated with concentrated extracts of trans-
genic N. tabacum or recombinant-TMV-infected N. benthamiana. The first in-
oculum (1 ml of extract) was administered by subcutaneous (three sites) and
intramuscular (one site) injection. An additional two booster inoculations con-
sisting of 500 l protein extract mixed in a ratio of 1:1 with Freund’s incomplete
adjuvant were administered as described above on days 23 and 41. Serum was
collected on days 1, 23, 41, and 51 and analyzed by direct ELISA and Western
blotting (1:20 dilution) against CRPV L1 insect cell-derived VLPs at a concen-
tration of 1.2 g/ml.
Preimmune sera all displayed high reactivity to normal plant proteins and to
baculovirus and insect cell proteins, probably because of exposure of rabbits to
these proteins via feed. Consequently, all sera were preabsorbed with nontrans-
genic plant extract and nonrecombinant baculovirus insect cell debris by incu-
bating serum dilutions with nitrocellulose membrane pieces (100 cm2) which
had been coated with the respective antigens as raw homogenates and then
washed and blocked as for Western blots (36).
Challenge of rabbits with infectious CRPV. Challenge of immunized rabbits
with infectious CRPV virus stock was performed according to a method used by
the Christensen group (6, 9). The rabbits were in four groups: group 1 was three
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animals immunized with transgenic plant-derived CRPV L1 protein, group 2 was
three animals immunized with TMV-derived CRPV L1 protein, group 3 was a
control group of four animals immunized with Mycobacterium bovis bacillus
Calmette-Gue´rin (BCG) expressing an irrelevant rotavirus protein, and group 4
was a positive control group of five animals immunized with insect cell-derived
CRPV VLPs. The two control groups received three immunizations at 2-week
intervals as described previously (21). At 10 weeks after the final immunization,
the two groups of animals immunized with plant-produced CRPV were chal-
lenged, while the two control groups were challenged 6 weeks after last inocu-
lation. It has previously been shown by our group that the timing of challenge
does not play a significant role in determining response within the parameters
used in these experiments (21). All rabbits were challenged with infectious
CRPV stock: each rabbit was inoculated at two sites for each dilution of the
infectious virus stock (102 and 103), and a 103 dilution of the virus stock
produces papillomas at 50% of challenged sites (9). Papilloma size was measured
as length by width by height in millimeters starting 14 days postchallenge. The
geometric mean diameter (GMD) was calculated for each papilloma. The means
and standard deviations for the GMDs in each treatment group were plotted
against time after challenge with virus.
Western blot analysis of sera. CRPV L1 expressed in insect cells was dena-
tured at 100°C for 10 min in sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS PAGE) gel loading buffer with reducing agents. The denatured
protein extracts were resolved on a 12% SDS-PAGE gel and electrophoretically
blotted (Trans-Blot Semi-Dry, Transfer Cell; Bio-Rad) onto nitrocellulose mem-
brane. The membrane was blocked in 5% nonfat milk in PBS for 1 h and
incubated in prebleed sera or day 51 sera from rabbits inoculated with plant-
produced CRPV L1 protein. The blot was probed with goat anti-rabbit alkaline
phosphatase-conjugated secondary antibody (Sigma) at a dilution of 1:5,000, and
binding was detected with 5-bromo-4-chloro-3-indolylphosphate (BCIP) and
4-nitroblue tetrazolium chloride in substrate buffer (Roche).
Virus neutralization experiments. CRPV L1 pseudovirions were generated
according to the protocol described by Pastrana et al. (33), with plasmids ob-
tained from John Schiller (Laboratory of Cellular Oncology, National Cancer
Institute, Bethesda, Md.). Sera from inoculated rabbits collected on the last day
of the experiment (day 51) as well as the preinoculation sera (day 1) were
evaluated for their capability to neutralize the CRPV pseudovirions in vitro as
described previously (33). Threefold dilutions of all pre- and postinoculation sera
ranging from 1:25 to 1:12,150 were prepared, sera were incubated with CRPV
pseudovirions, and the resulting secreted alkaline phosphatase (SEAP) content
was determined by application of the Great ESCAPE SEAP chemiluminescence
kit (BD Clontech) according to the manufacturer’s instructions.
RESULTS
Genetic analysis of transgenic plants. Wild-type N. tabacum
leaf disks were successfully transformed with A. tumefaciens
carrying the pART27 CRPV L1 binary vector, and putative
transgenic plants were regenerated and screened for the
CRPV L1 gene by PCR. Integration of the L1 gene was con-
firmed in 5 out of 15 regenerated N. tabacum lines. R0 gener-
ation plants were grown until sexual maturity and self-polli-
nated under controlled conditions, and the T1 generation seeds
were harvested. These were germinated on kanamycin-con-
taining tissue culture media. Total genomic DNA was ex-
tracted from T1 generation plantlets of the respective trans-
genic lines and again screened by PCR. A 1.5-kb amplicon was
generated by PCR for all five transgenic lines, indicating the
integration and confirming the inheritance of the CRPV L1
gene (data not shown).
Total RNA was extracted from individual transgenic plants
and analyzed for CRPV L1 gene transcription. RT-PCR prod-
ucts resulting from the amplification of an internal gene frag-
ment indicated that the integrated gene is transcribed in all
confirmed transgenic plants (Fig. 1A).
Expression of CRPV L1 in TMV-infected plants. Plants were
mechanically inoculated with synthesized transcripts of the re-
spective recombinant TMV vectors and closely monitored for
a period of 14 days. During the observation period, control
plants infected with the pBSG1057 vector expressing the green
fluorescent protein (GFP) were closely monitored using a UV
lamp. GFP expression throughout all leaves of control plants
was synonymous with the appearance of leaf curling and mo-
saic patterns.
On the day prior to harvesting the infected N. benthamiana
plants (day 13), leaf disk samples were taken from each leaf,
from the inoculated leaf to the last leaf on the apex, and total
RNA was extracted. RT-PCR analysis was performed to con-
firm the presence of CRPV L1 mRNAs (Fig. 1B).
Low levels of expression of the CRPV L1 gene could be
detected in the inoculated leaf through to the fifth leaf, after
which it was not possible to detect the 421-bp amplicon (Fig.
1B). Concurrent RT-PCR analysis detected the 474-bp TMV
coat protein mRNA in all leaves of infected plants, confirming
the systemic spread of TMV from the inoculated leaf to the
apical leaf (see Fig. 2B). This indicates deletion of the trans-
gene in the vector; this has been seen previously with TMV
expressing HPV-16 L1 (41).
Concentration of plant-derived CRPV L1 protein. Plant ma-
terial was harvested, processed, concentrated, and character-
ized by direct ELISA using conformation-specific and neutral-
izing MAb CRPV:5A and surface linear epitope-specific MAb
CRPV:10B. The TMV-infected plants were harvested 14 days
postinoculation once expression of the CRPV L1 genes was
confirmed by RT-PCR. The conformation-specific MAb
CRPV:5A bound strongly to both plant extracts (optical den-
sity at 405 nm [OD405] 1 and 0.6 for transgenic and transient
material, respectively), and MAb CRPV:10B slightly less so
(OD405  0.5 and 0.2 for transgenic and transient material,
respectively). The strong binding of the conformation-specific
MAb CRPV:5A with the plant extracts suggests that most of
the plant-derived protein is assembling into higher-order struc-
tures displaying appropriate conformational epitopes. Further-
more, the surface-linear-epitope-specific MAb CRPV:10B also
bound strongly, indicating the presence of L1.
The amount of plant-derived CRPV L1 protein was mea-
sured by comparison to a standard curve of the OD405 values
plotted against known concentrations of insect cell-derived
CRPV L1 protein in the colorimetric ELISA (data not shown).
Nontransgenic plant protein extract was spiked with insect
cell-derived CRPV L1 VLPs, resulting in a known concentra-
tion of 0.12 g per well (100 l). The amount of CRPV L1
produced in transgenic plants ranged from 0.4 to 1 mg/kg, and
CRPV L1 protein from infected N. benthamiana plants ranged
from 0.15 to 0.6 mg/kg of total leaf mass.
Electron microscopy of plant-derived protein extracts. Pre-
liminary experiments showed that the immunotrapping and
decorating protocol efficiently trapped and labeled intact insect
cell-derived VLPs and capsomeres (data not shown). Results
from transgenic extracts (Fig. 2) show that both gold-labeled
MAbs bound presumptive CRPV L1 protein, with no evidence
of any VLP-like structures, but evidence of capsomeres or
smaller aggregates (compare Fig. 2B and D with C and E).
Analyses of the TMV-derived CRPV L1 protein extract
were qualitatively identical, with no distinct higher-order struc-
tures seen after trapping with the CRPV:5A MAb. Parallel
analyses of proteins extracted from a noninfected N. benthamiana
plant showed no MAb binding at all (Fig. 2C and E).
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Analysis of the immune response of animals. Two groups of
three rabbits were immunized with transgenic-plant-derived
(rabbits 901, 902, and 903) or transiently expressed (rabbits
904, 905, and 924) CRPV L1 protein extract. The initial 1-ml
inoculum contained approximately 22 g to 50 g or 2 to 8 g
CRPV L1 from transgenic or recombinant-TMV-infected
plant extract, respectively. Serum was evaluated by direct
ELISA (1:20 dilution) against insect cell-derived CRPV L1
VLPs at a concentration of 0.12 g/well (Fig. 3A and B).
These results show that immunization of the rabbits with
transgenic-plant-derived CRPV L1 protein elicits a type-spe-
cific antibody response (Fig. 3A). Rabbit 902 shows the weak-
est response of the three animals on day 51. Rabbits 902 and
903 show increasingly elevated antibody responses to CRPV
L1 VLPs over the course of 51 days in comparison to their
respective antiserum reactivity on day 1. Analysis of the sera
collected from rabbits inoculated with TMV-derived CRPV L1
protein is shown in Fig. 3B. Rabbit 905 showed the strongest
reactivity for antisera collected on day 51. Although not to the
same magnitude, a similar trend in increasing reaction levels
was observed for the sera collected from rabbits 904 and 924.
To confirm the results presented in Fig. 4A and B, the
preabsorbed prebleed (day 1) and last-bleed (day 51) sera
collected from all six rabbits were tested by Western blotting
against denatured insect cell-derived CRPV L1 protein. All the
last-bleed sera collected from all rabbits injected with L1-
containing protein extracts were capable of specifically binding
denatured CRPV L1 protein (data not shown).
Rabbit challenge and CRPV pseudovirus neutralization as-
say. The data presented in Fig. 4 indicate that vaccination of
rabbits with plant-derived CRPV L1 protein does protect from
challenge with the higher dosage (102 dilution) of infectious
virus. Over the course of 63 days, vaccination did not entirely
prevent the growth of papillomas in one animal (903) but
FIG. 1. RT-PCR RNA analysis of (A) PCR-positive transgenic N. tabacum plants from the T1 generation and (B) N. benthamiana plants 13
days after inoculation with TMV-CRPV L1 synthesized transcripts. In panel B total RNA samples were also analyzed for the TMV coat protein
mRNA. The amplification of a 421-bp product by RT-PCR indicates the presence of the CRPV L1 transcript within total plant RNA. Total RNA
extracted from a noninfected/nontransgenic tobacco plant is the negative control; positive controls are synthesized transcripts prepared from
pBSG-CRPV L1 plasmid DNA.
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drastically reduced the average size of papillomas. The other
two rabbits (901 and 902) immunized with transgenic-plant
extract formed no papillomas. Rabbit 905, immunized with
TMV-derived extract, developed papillomas only on day 35 of
this experiment. Measurements taken on day 35 showed pap-
illomas of 0.5 mm in diameter. On the final day (day 63), this
diameter had increased to approximately 1 mm. In contrast,
the remaining two challenged rabbits (rabbit 904 and rabbit
924) had already developed papillomas on day 14. Measure-
ments showed that the diameters of papillomas on the backs of
rabbits 904 and 924 were around 0.8 mm and 1.45 mm, respec-
tively. Over the period of 63 days these papillomas grew in size,
resulting in measurements of 2 mm and 2.1 mm for rabbits 904
and 924, respectively. In comparison to the control group dis-
playing an average papilloma size of 13 mm on day 63 (all four
animals affected), the sizes of papillomas were reduced by
approximately 6.5-fold in the group vaccinated with the trans-
genic- or TMV-infected-plant-derived CRPV L1 protein.
Serum collected from all animals was tested for the ability to
neutralize CRPV pseudoviruses in vitro. Serum collected from
naive rabbits before vaccination was also tested, and, as ex-
pected, the absence of type-specific antibodies in the serum
resulted in the expression of alkaline phosphatase, thereby
confirming the inability of the serum to neutralize the CRPV
pseudovirus. However, no neutralization of the pseudovirus
was observed in the postinoculation serum (day 51) harvested
from all animals up to a dilution of 1/25. The included internal
positive-control serum, collected from rabbits that were previ-
ously immunized with insect cell-derived CRPV VLPs, show
neutralization of the virus up to and including the 1:450
FIG. 2. Electron micrograph images of immunogold-labeled CRPV L1 protein extracted from transgenic N. tabacum (A and B). Plant protein
extract was trapped onto carbon-coated copper grids using anti-CRPV L1 rabbit polyclonal antiserum, decorated with monoclonal antibodies
CRPV:5A (A) and CRPV:10B (B), and detected with an anti-mouse gold-conjugated secondary antibody. Gold particles are 30 nm in diameter.
(C) Nontransformed N. tabacum plant protein extract. (E) Noninfected N. benthamiana protein extract. (D) TMV-derived CRPV L1 protein
extract immunogold labeled with CRPV MAb 5A. Scale bars  100 nm.
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dilution. The known CRPV conformation-specific and neu-
tralizing MAb CRPV:5A, derived from a hybridoma, is ca-
pable of neutralizing the CRPV pseudovirus at a much
higher dilution of 105.
DISCUSSION
The aims of this study were to determine, first, whether or
not wild-type CRPV L1 could be produced in plants; second,
whether or not the plant-produced L1 protein was capable of
eliciting a type-specific antibody immune response; and third,
and most importantly, to see if this response could protect
against challenge by the live virus. Here we report the first
successful expression in plants of CRPV L1, both in transgenic
N. tabacum and via transient expression in N. benthamiana
using a TMV-based plant virus vector. While the protein did
not appear to assemble into higher-order structures, it did
react with conformation-specific and neutralizing MAbs and it
did elicit CRPV L1-specific antibodies. While these were ap-
parently not capable of neutralizing pseudovirion infectivity in
the assay system, rabbits were protected against developing
disease after virus challenge. This is therefore the first report
of the efficacy of any plant-derived papillomavirus vaccine.
HPV L1s have been expressed in transgenic plants previ-
ously at a very wide range of concentrations: Biemelt et al. (1)
achieved a yield of 12 mg/kg of L1 from a human codon-
optimized HPV-16 L1 gene in potatoes, Warzecha et al. (44)
got20 g/kg L1 VLPs from a plant codon-optimized HPV-11
L1 gene in potato tubers, Varsani et al. (40) got 4 g/kg leaf
tissue of HPV-16 L1 in tobacco from a native viral gene, and
Liu et al. (29) got 0.05% total soluble leaf protein (around 3
mg/kg in our hands) in tobacco from a presumably native gene.
The expression level achieved for CRPV L1 in our transgenic
tobacco (1 mg/kg) was reasonable in light of these results,
and especially so given that an unmodified viral gene was used.
However, it is not up to the level (1% total soluble leaf protein)
FIG. 3. Analysis of serum collected from New Zealand White rab-
bits inoculated with transgenic (A) or transiently derived (B) CRPV L1
protein extract. Serum collected over 51 days was tested against insect
cell-derived CRPV L1 VLPs at a concentration of 0.12 g/well.
FIG. 4. Papilloma growth on the backs of rabbits following challenge with infectious CRPV. Papilloma sizes were measured weekly beginning
at day 14 and the GMDs calculated. The mean GMDs and standard errors of the means of papillomas were plotted against time for the sites
challenged with the 102 dilution of infectious CRPV. The control group was immunized with BCG expressing irrelevant rotavirus antigen. CRPV
VLPs, rabbits immunized with purified CRPV L1 VLPs produced via baculovirus in insect cells. Data from rabbits 901 and 902, which showed no
papilloma growth, are included.
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considered as being the lower limit for commercial exploitation
(15) and as justifying industrial purification. Increasing this
expression level is not a trivial matter and is not apparently
amenable to prediction; for example, Warzecha et al. (44)
achieved only very low expression levels of a plant codon-
optimized HPV-11 L1 gene in transgenic potatoes, while our
group has achieved much higher levels in transgenic tobacco
using a native viral HPV-11 L1 gene (25). Biemelt et al. (1)
also found a human codon-optimized HPV-16 L1 expressed far
better than a native or a plant-optimized version.
Given that various virus-based transient expression systems
are known to allow for the synthesis of large amounts of anti-
gen within a short period of time (15, 16), we investigated the
TMV-based transient expression system to determine if we
could obtain higher yields of protein. Our group has also ex-
pressed HPV-16 L1 transiently in Nicotiana benthamiana via
the same TMV vector as used here; this allowed a 10-fold
increase in production over the transgenic case (41). However,
yields of CRPV L1 were lower than those obtained with trans-
genic plants (0.4 mg/kg versus 1 mg/kg); this was unex-
pected, but virus-based expression systems do have the disad-
vantage that the gene needs to be stably expressed, which is not
always guaranteed. Our results showed that the mRNA for
CRPV L1 was expressed only in the first five leaves, while the
TMV coat protein mRNA was expressed in leaves 1 (inocu-
lated) through 9. This suggests that the CRPV L1 gene must
have been excised and that the recombinant virus had reverted
back to wild type. Rabindran and Dawson (34) have previously
shown, using the same vector, that sequences were deleted
from the recombinant virus on passage from plant to plant,
resulting in loss of GFP expression; this also happens with the
wild-type HPV-16 L1 gene in recombinant TMV (41). Donson
et al. (13) found evidence that the size of the inserted gene was
the direct cause of vector instability, and the L1 gene is at the
upper limit of sequences to have been expressed successfully in
this vector (K. E. Palmer, Large Scale Biology Corp., personal
communication).
While the expression levels of the L1 protein in plants in this
work were too low for commercial exploitation, both the ex-
pression systems used here can be significantly improved: our
group has shown in other work that it is possible to achieve
yield increases in transient and transgenic expression of
HPV-16 L1 of several orders of magnitude, by an optimization
procedure involving a combination of vector choice, subcellu-
lar localization, and codon optimization (J. Maclean, M.
Koekemoer, A. J. Olivier, D. Stewart, I. Hitzeroth, T. Radema-
cher, R. Fischer, A.-L. Williamson, and E. P. Rybicki, unpub-
lished results).
The transgenic-plant- and TMV-derived CRPV L1 protein
apparently does not assemble into VLPs, but apparently only
into capsomeres and possibly other aggregates (Fig. 3A); this is
in contrast to the reported assembly of the HPV L1 proteins
into 55-nm VLPs in plants and the proven assembly of the
CRPV protein expressed from the same gene in insect cells in
our hands. This is most probably due to low protein concen-
trations that are not capable of driving the equilibrium towards
the assembly of VLPs; this has been postulated as the reason
for the predominance of lower-order structures in HPV L1
transgenic plants (1, 40, 41). However, in this case it appears as
though the assembly of CRPV capsids requires a significantly
higher L1 concentration than do either HPV-11 or HPV-16
VLPs, given that VLPs could be seen in tobacco expressing
only 4 g/kg of HPV-16 L1 (40). While the electron micro-
scope study detected no obvious higher-order structures bigger
than pentamers (10 nm in diameter), the trapping of these
and immunogold labeling of protein by the conformation-spe-
cific and neutralizing MAb CRPV:5A are proof that the pro-
tein assembled into an antigenically appropriate form. We note
that, while papillomavirus VLPs are the “gold standard” in
current vaccine development, capsomere-only vaccines have
also been shown to be effective in eliciting both neutralizing
antibodies (35) and cytotoxic T lymphocytes capable of causing
tumor regression (32).
A relatively strong CRPV L1-specific immune response was
elicited by the plant-derived protein in all rabbits immunized.
It was noteworthy that, in the case of the TMV-derived pro-
tein, immunization with only 2 to 8 g of L1 protein per dose
elicited an immune response equivalent to the 30 g of L1
derived from transgenic plant material. While Zhang et al. (45)
have demonstrated that HPV-6b VLPs are potent immuno-
gens in the absence of adjuvant, our immunogen was not in this
form. However, Franconi et al. (17, 18) have found that crude
extracts of N. benthamiana sap containing HPV-16 E7 protein
expressed via a potato virus X vector have a potent natural
adjuvant activity, which could potentially be exploited to the
advantage of plant-expressed vaccines. The same activity prob-
ably contributed to the response in our rabbits.
We further determined whether the immune response in
rabbits resulting from inoculation with plant-derived CRPV L1
protein was capable of protecting the animals from wart de-
velopment upon live-virus challenge. Results were obtained
which compared very favorably with the baculovirus-produced
CRPV L1 VLP positive-control model used both here and in a
parallel study (21), with all immunized animals being effec-
tively protected from disease. This compares well with other
studies of the efficacy in animals of plant-derived vaccine an-
tigens, such as the protection of rabbits from lethal challenge
with rabbit hemorrhagic disease virus by vaccination with VP60
protein produced in N. benthamiana via potato virus X (14)
and the protection of beagles from infection by canine parvo-
virus (CPV) by administration of a UV-inactivated recombi-
nant cowpea mosaic virus displaying a CPV VP2 capsid protein
epitope (17 amino acids) fused to the coat protein and dis-
played on the surface of the virus particle (26). Moreover, ours
is the first successful test of efficacy in an animal model system
of a plant-produced vaccine equivalent to vaccines of proven
efficacy for a major human disease pathogen (22, 42) and as
such represents an important proof of concept.
Protective immunity against HPV in particular, but also
against all PVs tested so far, is assumed to be due to the
presence of virus-neutralizing antibodies (30). Various animal
immunization and subsequent challenge experiments per-
formed using PV subunit vaccines on rabbits, cattle, and dogs
have been found to protect their respective hosts from chal-
lenge with live virus and have resulted in the induction of
virus-neutralizing antibodies (4, 24). However, in this study we
were unable, using a relatively new PV pseudovirion neutral-
ization assay, to demonstrate the presence of infectivity-neu-
tralizing antibodies in the sera of immunized rabbits that were
subsequently shown to be protected against CRPV infection,
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albeit in antiserum diluted 25-fold. In our hands it has
proved difficult to prove neutralizing activity in anti-PV L1 sera
diluted 50-fold, and it may be that the older live-virus infec-
tivity neutralization tests are more sensitive (D. Stewart, un-
published results). We note that Suzich et al. (38) found only
a low titer of neutralizing antibodies in dogs protected by L1
vaccination against canine oral papillomavirus infection and
cautioned that the levels of virus-neutralizing antibodies might
be underestimated. Indeed, others in our research group have
previously demonstrated protection of rabbits against CRPV
infection by vaccination with BCG-vectored CRPV L1, with
only very weak demonstration of neutralizing antibodies by the
same assay as used here (21). It is also possible that protection
from virus challenge in our case could be by stimulation of the
cell-mediated immune response, as this has been argued to be
an underappreciated component of PV immunity and clear-
ance of warts and other lesions or tumors (10, 31, 32); however,
this was not explicitly investigated.
In conclusion, this is the first report that shows that the
plant-produced papillomavirus L1 protein can be used as a
vaccine capable of protecting against challenge by live virus.
This is a valuable first step towards the production of an HPV
vaccine by a system that is cheap enough to be used in and for
developing countries.
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